摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-4-(3-methylpiperazin-1-yl)phenylamine | 915722-91-7

中文名称
——
中文别名
——
英文名称
(R)-4-(3-methylpiperazin-1-yl)phenylamine
英文别名
4-[(3R)-3-methylpiperazin-1-yl]aniline
(R)-4-(3-methylpiperazin-1-yl)phenylamine化学式
CAS
915722-91-7
化学式
C11H17N3
mdl
——
分子量
191.276
InChiKey
DJVJJFDZNRYSHR-SECBINFHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    379.6±27.0 °C(Predicted)
  • 密度:
    1.062±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    41.3
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (R)-4-(3-methylpiperazin-1-yl)phenylamine 在 lithium aluminium tetrahydride 、 对甲苯磺酸 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 2.83h, 生成 (R)-{4-[4-(3-methylpiperazin-1-yl)phenylamino]quinolin-3-yl}methanol
    参考文献:
    名称:
    Structure−Activity Relationship of Quinoline Derivatives as Potent and Selective α2C-Adrenoceptor Antagonists
    摘要:
    Starting from two acridine compounds identified in a high-throughput screening campaign (1 and 2, Table 1), a series of 4-aminoquinolines was synthesized and tested for their properties on the human alpha(2)-adrenoceptor subtypes (alpha(2A), alpha(2B), and alpha(2C.)). A number of compounds with good antagonist potencies against the alpha(2C)-adrenoceptor and excellent subtype selectivities over the other two subtypes were discovered. For example, (R)-{4-[4-(3,4-dimethylpiperazin-1-yl) phenylamino] quinolin- 3- yl} methanol 6j had an antagonist potency of 8.5 nM against, and a subtype selectivity of more than 200-fold for, the alpha(2C)-adrenoceptor. Investigation of the structure-activity relationship identified a number of structural features, the most critical of which was an absolute need for a substituent in the 3-position of the quinoline ring. The 3-position on the piperazine ring was also found to play an appreciable role, as substitutions in that position exerted a significant and stereospecific beneficial effect on the alpha(2C)-adrenoceptor affinity and potency. Replacing the piperazine ring proved difficult, with 1,4-diazepanes representing the only viable alternative.
    DOI:
    10.1021/jm060262x
  • 作为产物:
    描述:
    (R)-3-methyl-1-(4-nitrophenyl)piperazine 在 palladium on activated charcoal 氢气 作用下, 以 乙醇 为溶剂, 以88%的产率得到(R)-4-(3-methylpiperazin-1-yl)phenylamine
    参考文献:
    名称:
    Structure−Activity Relationship of Quinoline Derivatives as Potent and Selective α2C-Adrenoceptor Antagonists
    摘要:
    Starting from two acridine compounds identified in a high-throughput screening campaign (1 and 2, Table 1), a series of 4-aminoquinolines was synthesized and tested for their properties on the human alpha(2)-adrenoceptor subtypes (alpha(2A), alpha(2B), and alpha(2C.)). A number of compounds with good antagonist potencies against the alpha(2C)-adrenoceptor and excellent subtype selectivities over the other two subtypes were discovered. For example, (R)-{4-[4-(3,4-dimethylpiperazin-1-yl) phenylamino] quinolin- 3- yl} methanol 6j had an antagonist potency of 8.5 nM against, and a subtype selectivity of more than 200-fold for, the alpha(2C)-adrenoceptor. Investigation of the structure-activity relationship identified a number of structural features, the most critical of which was an absolute need for a substituent in the 3-position of the quinoline ring. The 3-position on the piperazine ring was also found to play an appreciable role, as substitutions in that position exerted a significant and stereospecific beneficial effect on the alpha(2C)-adrenoceptor affinity and potency. Replacing the piperazine ring proved difficult, with 1,4-diazepanes representing the only viable alternative.
    DOI:
    10.1021/jm060262x
点击查看最新优质反应信息

文献信息

  • PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS
    申请人:Almac Discovery Limited
    公开号:EP3083625B1
    公开(公告)日:2017-11-01
  • US9850247B2
    申请人:——
    公开号:US9850247B2
    公开(公告)日:2017-12-26
查看更多